期刊文献+

卵巢癌患者围手术期细胞免疫功能变化的临床意义 被引量:1

Significance of the changes of perioperative immune status in ovarian tumor
下载PDF
导出
摘要 目的 研究手术对卵巢癌患者免疫功能状况的影响及其临床意义。方法 应用间接免疫荧光法、MTT比色法、ELISA检测围手术期卵巢癌患者外周血淋巴细胞 (PBL)T淋巴细胞亚群、自然杀伤 (NK)活性及血清可溶性白介素 2受体 (rIL 2R)。结果 卵巢癌患者PBL中CD3+ 、CD4+ 、CD4+ /CD8+ 及NK活性均明显低于良性肿瘤组 ,而Tac+ 、rIL 2R明显升高 ;手术后患者T细胞亚群 ,NK活性无明显改变 ,但rIL 2R显著减少。结论 卵巢癌患者机体免疫功能存在明显的抑制 ,手术大块切除肿瘤有利于自身抗瘤活性的恢复。血清rIL Objective To evaluate the operative effect on the immune status of patients with malignant ovarian tumor(MOV) and clinical significance.Methods The T lymphocyte subsets, natural killer(NK) activity and the levels of soluble interleukin 2 receptors(rIL 2R) wre measured in 30 patients with MOV and 25 benign controls(BC) by sandwich ELISA, indirect immune fluorescence and MTT colorimetry.Results The numbers of CD3 +,CD4 +,CD4 +/CD8 + and NK activity in the patients were lower than those in the BC significantly, and the opposite results were observed about CD8 +,Tac + and sIL 2R( P <0 01~0 001);There were no remarkable difference postoperatively in T lymphocyte subsets, as well as the NK activity, while the levels of rIL 2R decreased.Conclusion The immune status of MOV was depressed, especially the cellular immunity.After resection, the immunity improved. The levels of sIL 2R could indicate the size of tumor in vivo.
出处 《重庆医学》 CAS CSCD 2002年第3期193-194,共2页 Chongqing medicine
关键词 卵巢肿瘤 T细胞亚群 NK活性 rIL-2R 卵巢癌 围手术期 细胞免疫功能 临床意义 malignant ovarian tumor operation T lymphocyte subsets NK activity soluble interleukin 2 receptor
  • 相关文献

参考文献9

  • 1[1]Lotze MT, Finn QJ. Recent advance in celluar immunology: implication for immunity to cancer[J].Immunol Today,1990,11:190.
  • 2[2]Lissoni P, Bami S, Rovelli F, et al. The biological significance of soluble interleukin-2 receptors in solid tumors[J].Eur J Cancer,1990,26:33.
  • 3[3]Schondorf T, Engel H, Lindemann C. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours[J].Cancer Immunol Immunother,1997,44(2):88.
  • 4[4]Schroder W, Lering A, Stegmuller M, et al. Lymphocyte subsets in patients with ovarian and breast cancer[J].Eur J Gynaecol Oncol,1997,18(6):474.
  • 5[5]Rubin LA, Nelson DL. The soluble interleukin-2 receptors:biology, function, and clinical application[J].Ann Inter Med,1990,113:619.
  • 6[6]Barton DP, Blanchard DK, Wells AF. Expression of interleukin-2 receptor alpha (IL-2R alpha) mRNA and protein in advanced epithelial ovarian cancer[J].Anticancer Res,1994 May-Jun,14(3A):761.
  • 7[7]Chen CK, Wu MY, CHao KH, et al. lymphocytes and cytokine production in ascitic fluid of ovarian malignancies[J].J Formos Med Assoc,1999,Jan,98(1):24.
  • 8[8]Wang S, Cai G, Lu Y. Clinical implication of serum sIL-2R levels in ovarian cancer[J].J Tongji Med Univ,1998,18(2):126.
  • 9[9]Gebauer G, Rieger M, Jager W. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors[J].Anticancer Res,1999 Jul-Aug,19(4A):2509.

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部